Mar 4, 2026 07:00AM
Mar 2, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 25, 2026 07:00AM
Feb 24, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM EyePoint Appoints Michael Campbell as Chief Commercial Officer
Feb 17, 2026 07:00AM
Feb 5, 2026 07:00AM
Jan 16, 2026 07:00AM
Jan 7, 2026 09:02AM
Jan 7, 2026 07:03AM
Jan 7, 2026 07:00AM
Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026
Dec 17, 2025 07:00AM
Dec 16, 2025 07:00AM
Dec 9, 2025 10:49AM
Nov 19, 2025 07:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 07:00AM
Nov 5, 2025 07:00AM EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Nov 3, 2025 07:00AM
Oct 29, 2025 07:00AM
Oct 16, 2025 07:00AM
Oct 14, 2025 10:43PM
Oct 14, 2025 10:43PM
Oct 14, 2025 04:35PM
Oct 14, 2025 04:35PM EyePoint Announces Proposed Public Offering of Common Stock
Oct 14, 2025 04:01PM
Oct 14, 2025 04:01PM
Sep 16, 2025 07:00AM
Aug 26, 2025 07:00AM
Aug 18, 2025 04:01PM
Aug 6, 2025 07:30AM
Aug 6, 2025 07:00AM EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Jul 30, 2025 07:00AM
Jul 29, 2025 07:00AM
Jul 29, 2025 07:00AM
Jul 16, 2025 07:00AM
Jun 16, 2025 07:00AM
May 28, 2025 04:01PM
May 27, 2025 07:00AM EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
May 16, 2025 07:00AM
May 13, 2025 07:00AM
May 7, 2025 07:00AM
Apr 30, 2025 07:00AM
Apr 16, 2025 07:00AM
Mar 27, 2025 07:00AM
Mar 17, 2025 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 5, 2025 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All